Year: 2025

NanoViricides Dual Track Clinical Strategy Explained by a Research Report – Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolioOmeros is...

Safex Chemicals India Ltd. Receives Frost & Sullivan’s 2025 Global Competitive Strategy Leadership Recognition for Excellence in Crop Protection Chemicals

Safex earns global recognition for its innovation-driven strategy, digital transformation, and customer-centric approach in the evolving crop protection chemicals industry....

DOCREPLAY.ai Unveils WHY+: Breakthrough Hybrid AI Platform Redefines Voice Technology and Sets a Higher Industry Standard for Qualitative Research at Scale

Purpose-built AI platform integrates intelligent agent technology with proprietary voice capture to deliver practical healthcare intelligence at scale while eliminating...

error: Content is protected !!